Device Trial Radar · NCT07369180
NQ Square TMS for Major Depressive Disorder: One Day, Three Sessions in Adults
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Jan 15, 2026
Primary completion
Mar 9, 2026
Study completion Jun 18, 2026
Sponsor
- Lead sponsor
- NeuroQore Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jan 27, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Transcranial Magnetic Stimulation (TMS) Therapy is a non-invasive procedure that uses magnetic pulses to stimulate the cortex (brain) to treat Major Depressive Disorder (MDD). Currently established therapy uses one 19-minute treatment session per day for 5 days per week for 6 weeks, for a total of 30 treatment sessions. The goal of this multi-site sham-controlled double-blinded randomized clinical trial is to evaluate the safety and effectiveness of accelerating the delivery of the NeuroQore Square TMS system's rectangular waveform rTMS protocol for the treatment of adults aged 22-85 with Major Depressive Disorder. The accelerated protocol of this study will involve the same currently FDA-cleared 19-min treatment session offered three times in a single day, with no additional treatment sessions.
Conditions
- Major Depressive Disorder
Interventions
Active Accelerated rTMS TreatmentDevice
1 Day x 3 Sessions of 19-minutes active rTMS treatment, with 60 minutes rest between sessions.
Sham Accelerated rTMS TreatmentDevice
1 Day x 3 Sessions of 19-minutes sham rTMS treatment, with 60 minutes rest between sessions. It simulates the treatment regimen but blocks the treatment from reaching the target in Cortex.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total ScoreTime frame: Baseline (treatment day, pre-treatment), immediately post-treatment, 24 hours, 7 days and 30 days post-treatment
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
LGTC Group
Campbell, California
LGTC Group
Sunnyvale, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.